NapaJen Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NapaJen Pharma, Inc. - overview
Established
2005
Location
Seattle, WA, US
Primary Industry
Biotechnology
About
Founded in 2005 and based in California, US, NapaJen Pharma, Inc. is a pharmaceutical company that engages in the research and development of drugs for hematopoietic stem cell transplantation in hematological cancers. The firm was founded as Napa Jenomics Corporation, and initially focused on nucleic acid drug discovery. In March 2024, INCJ, Inc.
exited all its stake in NapaJen Pharma, Inc. to KNC Laboratories Co. , Ltd. The firm as of August 2024, has operations internationally, including a subsidiary in Japan, and is led by its CEO, Kenji Arima.
NapaJen Pharma's technology platform addresses the significant challenges of delivering oligonucleotide drugs to target immune cells. By binding directly to the Dectin-1 receptor on antigen-presenting cells, their approach enhances the stability, bioavailability, and cellular uptake of these drugs. This technology accelerates the development process, from target identification to lead optimization. Additionally, the company operates a dual-pronged development strategy, managing both internal drug programs and collaborative projects with biotechnology and pharmaceutical companies.
Key offerings include their flagship therapeutic, NJA-730, which is in Phase 1 clinical trials and aims to treat acute graft-versus-host disease (GvHD).
Current Investors
Mitsui Global Investment, INCJ, Mizuho Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.napajen.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.